Denali Therapeutics Inc. DNLI Off-balance sheet concentrations of credit risk

Other financials

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Market cap$3.94B+95.2%

Enterprise value$3.59B+78.6%

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept dnli:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Denali Therapeutics Inc.'s off-balance sheet concentrations of credit risk?: Denali Therapeutics Inc. (DNLI) reported off-balance sheet concentrations of credit risk of $0 in Q1 2026.